Welcome to our dedicated page for Cardiff Oncology SEC filings (Ticker: CRDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cardiff Oncology, Inc. (Nasdaq: CRDF) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company focused on PLK1 inhibition and its lead asset onvansertib, Cardiff Oncology uses filings such as Forms 10-K, 10-Q and 8-K to report its financial condition, clinical development progress and material corporate events.
In recent Form 8-K filings, Cardiff Oncology has furnished press releases covering quarterly financial results, business updates and positive data from the randomized Phase 2 CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer. These filings also reference presentation materials for clinical data updates and summarize key milestones in the onvansertib program. Other 8-Ks document outcomes of the annual meeting of stockholders, including director elections, auditor ratification, equity plan amendments and advisory votes on executive compensation.
Through its periodic reports, such as Form 10-K and Form 10-Q, Cardiff Oncology discusses research and development expenses, royalty revenues, cash and investment balances, and risk factors associated with clinical-stage oncology drug development. These documents outline the company’s dependence on successful clinical trials, regulatory approvals and access to capital, as well as competitive and operational risks.
On Stock Titan, each filing is accompanied by AI-powered summaries that highlight the most important points, helping readers quickly understand complex financial tables, clinical program descriptions and legal language. Users can follow new filings in near real time as they are posted to EDGAR and use this page to review Cardiff Oncology’s historical regulatory record, including information relevant to governance, compensation, capital structure and the progress of onvansertib across multiple cancer indications.
Cardiff Oncology, Inc. reported that Chief Executive Officer Mani Mohindru received a grant of stock options covering 600,000 shares of common stock. These options have an exercise price of $1.62 per share and expire on March 31, 2036.
The grant is compensation-related, not an open-market trade. Following this award, the filing shows option holdings of 968,766 stock options. A footnote states that 150,000 options vest on March 31, 2027, with 12,500 options vesting monthly for 36 months thereafter, creating a multi-year vesting schedule.
Cardiff Oncology, Inc. entered into separation agreements on March 27, 2026 with former CEO Dr. Mark Erlander and former CFO James Levine, who had previously stepped down as part of a strategic review.
Dr. Erlander will receive his $635,000 base salary paid over 12 months from the separation date, his 2025 bonus of $122,238, 50% of his 2026 target bonus prorated over 12 months, and up to 12 months of continued healthcare benefits. He also signed a consulting agreement, and his stock options will continue to vest until June 2026, after which vested options are exercisable for 12 months.
Mr. Levine will receive his $490,000 base salary paid over 12 months, his 2025 bonus of $61,740, 50% of his 2026 target bonus prorated over 12 months, and up to 12 months of continued healthcare benefits. His vested stock options are exercisable for 12 months after the separation date. Both executives agreed to a general release and confidentiality, and on March 27, 2026, Dr. Erlander also resigned as a director.
Cardiff Oncology Inc: Ownership update by The Vanguard Group. The filing amends a Schedule 13G to report 0 shares beneficially owned, representing 0% of Common Stock as of the report. The filing notes an internal realignment at The Vanguard Group, Inc. effective January 12, 2026, with certain subsidiaries now reporting separately.
Cardiff Oncology furnished a corporate presentation highlighting new Phase 2 data for its oral PLK1 inhibitor onvansertib in first-line RAS‑mutated metastatic colorectal cancer. In the CRDF‑004 trial, onvansertib 30 mg plus FOLFIRI/bevacizumab showed a confirmed objective response rate of 72.2% versus 43.2% for standard chemotherapy regimens and a progression‑free survival hazard ratio of 0.38 versus FOLFIRI/bevacizumab, with median progression‑free survival not yet reached in the onvansertib arms at the January 22, 2026 cut. Safety data indicate no significant added toxicity, supporting selection of the 30 mg dose with FOLFIRI/bevacizumab for a planned registrational program. The company plans an FDA meeting in the first half of 2026 and aims to initiate a Phase 3 trial in the second half of 2026, and reports $58.3 million in cash, cash equivalents, and short‑term investments, funding operations into the first quarter of 2027.
Cardiff Oncology reported full-year 2025 results and highlighted strong Phase 2 data for onvansertib in first-line RAS-mutated metastatic colorectal cancer. In the CRDF-004 trial, the 30 mg onvansertib + FOLFIRI/bevacizumab arm achieved a confirmed objective response rate of 72.2%, versus 43.2% across combined standard-of-care arms, and showed significantly longer progression-free survival (hazard ratio 0.37, p<0.05).
The company plans to advance the 30 mg dose with FOLFIRI/bevacizumab into a planned registrational program, with detailed data and registrational plans expected in the first half of 2026 after FDA discussions. Leadership was realigned for late-stage development, including appointing Mani Mohindru as interim CEO.
Financially, 2025 royalty revenue was $593,000 and total operating expenses were $49.6 million. Net loss attributable to common stockholders was $45.9 million, or $0.69 per share, with weighted-average shares outstanding of 66.8 million. Cash, cash equivalents and short-term investments totaled $58.3 million as of December 31, 2025, which the company believes will fund operations into the first quarter of 2027.
Cardiff Oncology files its annual report describing a clinical‑stage pipeline centered on onvansertib, an oral, highly selective PLK1 inhibitor being tested across multiple cancers, led by a Phase 2 trial in first‑line RAS‑mutated metastatic colorectal cancer in partnership with Pfizer Ignite.
Updated CRDF‑004 data show a confirmed objective response rate of 72.2% for the 30 mg onvansertib plus FOLFIRI/bevacizumab arm versus 43.2% for standard of care, with a progression‑free survival hazard ratio of 0.37 versus standard of care and a generally well‑tolerated safety profile.
The company remains loss‑making, with a 2025 net loss of about $45.9 million, an accumulated deficit of roughly $430.0 million, cash and investments of $58.3 million, and substantial doubt about its ability to continue as a going concern, implying a need for additional capital. Cardiff also discloses a February 2026 notice from Nerviano alleging material breach of the onvansertib license; Cardiff disputes the claims but notes that an adverse outcome could jeopardize key intellectual property rights and materially harm its business.
Cardiff Oncology, Inc. reported that Chief Accounting Officer Lindsay Brigitte Ute acquired a grant of 200,000 stock options on February 13, 2026. The options were granted at an exercise price of $0.00 per share, reflecting a cost-free award rather than an open-market purchase.
Following this transaction, Ute held a total of 1,025,334 stock options directly. According to the vesting terms, 50,000 options vest on February 13, 2027, and 4,166 options vest monthly for the subsequent 36 months, spreading the remainder of the award over three years.
Mohindru Mani reported acquisition or exercise transactions in this Form 4 filing.
Cardiff Oncology, Inc. reported that Interim CEO and director Mani Mohindru received a grant of stock options. The award covers 200,000 stock options, recorded at a price of $0.0000 per option, and increases her directly held option position to 368,766 options following the transaction.
Cardiff Oncology chief accounting officer files initial holdings report. The Form 3 shows Brigitte Lindsay beneficially owns 27,431 shares of Cardiff Oncology common stock directly. She also holds multiple stock option awards on common stock with expiration dates from January 2028 through March 2035 and exercise prices ranging from $1.72 to $21.6 per share. Footnotes describe vesting schedules for each option grant, with portions already vested and additional shares vesting over monthly periods of up to 36 months.
Cardiff Oncology reported major leadership changes and a clinical program update. On January 27, 2026, longtime CEO Dr. Mark Erlander and CFO James Levine stepped down as part of a strategic leadership review. The Board appointed director Dr. Mani Mohindru as interim CEO and promoted Brigitte Lindsay, previously Senior Vice President, Finance, to Chief Accounting Officer.
The company also highlighted a positive update from CRDF-004, a randomized Phase 2 trial of its drug candidate onvansertib combined with standard-of-care regimens in first-line RAS‑mutated metastatic colorectal cancer. Details of the results are provided in an attached press release, which is largely incorporated by reference into this report.